[Anti-arrhythmia therapy with Ca++-antagonists].
A minireview is given of the theoretical and clinical knowledge relating to antiarrhythmic therapy with Ca++-antagonists. Following a brief recall of the basic cardiac electrophysiological elements, some primarily Ca++- and 'slow response'-dependent electropathological phenomena (ischaemia-induced local conduction delay, ST-T-alternans, early and delayed after depolarizations) are presented, to which roles are attributed in the development of re-entry, triggered automaticity and human cardiac arrhythmias. Next, those types of heart rhythm disturbances are discussed which can be treated in the hope of success with Ca++ entry blocking (class IV) antiarrhythmic agents.
Fazekas
T
T
D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D002121:Calcium Channel Blockers / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D013614:Tachycardia, Paroxysmal / Q000188:drug therapy; D013617:Tachycardia, Supraventricular / Q000145:classification / Q000188:drug therapy*; D014700:Verapamil / Q000627:therapeutic use
D002121:Calcium Channel Blockers; D014700:Verapamil
Antiaritmiás kezelés Ca++-antagonistákkal.